Frances: I'm afraid that number's ex-directory zimovane 3.75 mg gl The market potential for these drugs is enormous--Citigroup analysts estimated the field could be worth $35 billion--which no one is ignoring. Merck, Bristol-Myers and Roche are all hustling these programs along, devoting significant resources to fast-paced development programs and leaping into late-stage trials.